2021.May.07

Updates on the planned allocation of the cash raised from the 2018 fundraising

1. Date of the board of directors resolution for the change: May 7, 2021 2. Effective registration date of the original plan: Mar 25, 2019 3. Major change Reason for the change: The Company’s fundraising in 2018 with total amount of NT$ 2,025,000,000 was originally planned to be used for the development of five R&D […]

HOMEWhat’s NewAnnouncementsUpdates on the planned allocation of the cash raised from the 2018 fundraising

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2021.May.06

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study

2021.May.07

Announcement that the consolidated financial statements for the first quarter of 2021 were authorized for issuance by the Board of Directors